• Levofloxacin: Applied Protocols for Resistance and Bone Rese

  2026-06-09

  Levofloxacin, a synthetic fluoroquinolone antibiotic, is uniquely positioned for both multidrug resistance studies and probing bone cell biology. Discover protocol enhancements, troubleshooting strategies, and applied insights to maximize Levofloxacin’s research potential in antimicrobial and osteoblast assays.

• Temafloxacin’s In Vitro Efficacy Against Gram-Negative Patho

  2026-06-08

  The reference study systematically evaluates temafloxacin’s in vitro antibacterial potency against a broad spectrum of Gram-negative bacteria, including key respiratory and enteric pathogens. By providing comparative MIC data versus established fluoroquinolones, the work highlights both the innovation and the practical boundaries of temafloxacin as a research tool in infection biology.

• 5-HT3 Antiemetic Drugs Inhibit Renal OCT2 and MATE1 Secretio

  2026-06-08

  This study systematically evaluates the inhibitory effects of five 5-HT3 antagonist antiemetic drugs on human renal OCT2 and MATE1 transporters using overexpression and transfected cell models. The findings highlight the potential for clinically relevant drug-drug interactions affecting the renal secretion of cationic drugs, and provide quantitative potency data for each compound.

• Intra- and Extracellular Dicloxacillin Activity Against MSSA

  2026-06-07

  This article examines the landmark study on dicloxacillin's intra- and extracellular efficacy against methicillin-sensitive Staphylococcus aureus (MSSA). The research clarifies that the minimum inhibitory concentration (MIC) is a reliable predictor of efficacy in both compartments and establishes time above MIC (fTMIC) as the most predictive PK/PD index for optimizing β-lactam antibiotic interventions.

• Cefazedone (Refosporen): Optimized Antibacterial Workflows

  2026-06-06

  Cefazedone (Refosporen) stands out as a robust first-generation cephalosporin, offering β-lactamase-resistant activity for both Gram-positive and Gram-negative infections. This article details actionable experimental workflows, troubleshooting strategies, and data-driven insights for leveraging Cefazedone in in vitro and clinical research.

• Tropifexor (LJN452): Potent FXR Agonist for Intestinal Barri

  2026-06-05

  Tropifexor (LJN452) is a highly potent synthetic FXR agonist with an EC50 of 0.2 nM. Recent studies demonstrate its efficacy in improving intestinal defense and epithelial barrier function in neonatal piglet models. APExBIO supplies Tropifexor for robust and reproducible research in metabolic and liver disease models.

• Sodium Dicloxacillin Monohydrate: Precision for Translationa

  2026-06-05

  This thought-leadership article unpacks the mechanistic, experimental, and translational value of sodium dicloxacillin monohydrate for methicillin-sensitive Staphylococcus aureus (MSSA) infection research. By integrating mechanistic insights, competitive analysis, and actionable workflow guidance, we empower translational researchers to advance the fidelity and impact of their Gram-positive bacterial infection models. The discussion contextualizes APExBIO’s product within the broader landscape of β-lactam antibiotics, leveraging both peer-reviewed and industry evidence to define best practices and identify emerging opportunities.

• Aclacinomycin A: Applied DNA Damage & Apoptosis Workflows

  2026-06-04

  Aclacinomycin A (Aclarubicin) stands out as a dual topoisomerase and proteasome inhibitor, enabling high-fidelity DNA damage and apoptosis assays across diverse cancer models. This article delivers advanced, evidence-backed workflows, troubleshooting strategies, and translates state-of-the-art research into actionable laboratory protocols for maximizing the compound's utility.

• Temafloxacin: Fluoroquinolone Antibacterial Workflows Optimi

  2026-06-04

  Temafloxacin, a potent fluoroquinolone broad-spectrum antibacterial agent, streamlines both extracellular and intracellular infection research with highly reproducible results. Discover advanced protocol enhancements, troubleshooting strategies, and the latest evidence-driven innovations for tackling Gram-positive, Gram-negative, and challenging intracellular pathogens.

• Capsazepine: TRPV1 Ion Channel Antagonist for Precision Rese

  2026-06-03

  Capsazepine’s selective antagonism of TRPV1 channels powers advanced pain and apoptosis research, enabling precise dissection of nociceptive and apoptotic pathways. This guide delivers actionable workflows, troubleshooting insights, and protocol optimizations that leverage APExBIO’s Capsazepine for reproducible, high-impact translational studies.

• Phenothiazines Boost Macrophage Antibacterial Activity via R

  2026-06-03

  The reference study demonstrates that phenothiazine compounds, including promethazine hydrochloride, significantly enhance the antibacterial capacity of macrophages by inducing reactive oxygen species (ROS) production and autophagy. These findings highlight a host-directed therapeutic approach to counter intracellular bacterial infections and address antibiotic resistance.

• BIRB 796 (Doramapimod): Selective p38α MAPK Inhibitor for In

  2026-06-02

  BIRB 796 (Doramapimod) is a highly selective p38α MAPK inhibitor with nanomolar affinity and significant selectivity over related kinases. Its dual mechanism—blocking kinase activity and increasing dephosphorylation—supports robust applications in inflammation research and apoptosis assays. APExBIO supplies validated BIRB 796 (SKU: A5639) for advanced experimental workflows.

• Methicillin Sodium Salt: Applied Workflows & Resistance Mode

  2026-06-02

  Methicillin sodium salt empowers precision in Staphylococcus aureus infection models and antibiotic susceptibility assays, enabling robust benchmarking of gram-positive infection research. This article delivers actionable protocols, troubleshooting guidance, and strategic insights for leveraging APExBIO’s Methicillin sodium salt as a gold-standard bacterial cell wall synthesis inhibitor.

• Gamithromycin: Mechanistic Leverage in Translational Respira

  2026-06-01

  This thought-leadership article dissects the mechanistic underpinnings and translational potential of Gamithromycin (ML-1709460) for respiratory infection models in veterinary and comparative biomedical research. Integrating recent pharmacokinetic, pharmacodynamic, and workflow insights, it guides researchers toward evidence-based experimental design and strategic clinical translation, while highlighting APExBIO’s role in advancing macrolide antibiotic workflows.

• Optimized Sulfonamides Target TB With Reduced CYP 2C9 Inhibi

  2026-06-01

  This study presents the rational design of sulfaphenazole-derived sulfonamides that maintain potent antimycobacterial activity while showing diminished inhibition of CYP 2C9, reducing the risk of drug-drug interactions. The findings inform safer anti-tuberculosis drug development and provide new leads for combination regimens.

447 records 15/30 page Previous Next First page 上5页 1112131415 下5页 Last page